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Diagnosis of Mycoplasma pneumoniae Pneumonia
with Measurement of Speciﬁc Antibody-Secreting
Cells
Mycoplasma pneumoniae (Mp) is reported to be the most common
bacterial cause of community-acquired pneumonia (CAP) in
hospitalized U.S. children (1). However, current diagnostic tests,
including PCR of upper respiratory tract (URT) specimens and
serology, do not differentiate between Mp infection and carriage (2).
Mp carriage in the URT is found in up to 56% of healthy children
(2, 3). A >4-fold increase in IgG levels is still used in most centers to
conﬁrm Mp infection but has low sensitivity (4) and is not helpful in
acute clinical management (3). In the absence of an accurate diagnostic
test, it is not surprising that studies and meta-analyses on the efﬁcacy of
antibiotics are inconclusive for Mp CAP in children (5, 6).
Circulating antibody-secreting cell (ASC) responses have been
demonstrated to be more rapid and shorter-lived than antibody
responses (7). We hypothesized that Mp-IgM-ASCs circulate in
peripheral blood only for a few days or weeks after Mp infection,
whereas Mp-DNA in the URT and serum antibodies persist for
months. We aimed to evaluate the measurement of Mp-IgM-ASCs
by enzyme-linked immunospot (ELISpot) assay as a new test for
diagnosing Mp CAP.
Methods
Pediatric patients with CAP (n= 152) and control subjects (n= 156)
were enrolled from May 2016 to April 2017 after written informed
consent. Inclusion criteria for patients with CAP were clinical
diagnosis of pneumonia (fever .38.58C and tachypnea [8]) in
previously healthy children aged 3–18 years. Children ,3 years
were excluded because of a high probability of viral coexistence in
the URT (8). Control individuals included healthy children
(undergoing elective surgical procedures) and siblings of patients
with CAP (with higher chance of being asymptomatic carriers)
without recent (<1 wk) respiratory tract infections.
In all enrolled children, pharyngeal swabs were taken for Mp
real-time PCR (9). If additional consent was given, blood samples also
were collected in control individuals and patients with CAP (before
antibiotic treatment) to test for the presence of Mp-IgM-ASCs by
ELISpot assay (detailed in the legend of Figure 1) (10) and Mp-IgM,
Mp-IgG, and Mp-IgA by ELISA (2). Finally, we only included
children with fresh (isolated <4 h) peripheral blood mononuclear
cells to avoid poor ELISpot assay performance resulting from
decreased ASC viability (in case of isolation .4 h after sampling) or
reduced ASC recovery (after a freeze–thaw cycle) (10). Samples and
clinical data (using a standardized questionnaire) were collected at
follow-up visits at ,2 weeks, 2 weeks to 2 months, and 2–6 months.
Assuming that 15% of pairs switch from PCR to IgM-ASC
ELISpot assay (positive to negative) and 2% from IgM-ASC ELISpot
assay to PCR (negative to positive), we calculated a sample size of 85
children (patients and control subjects) to achieve 80% power and 5%
2-sided signiﬁcance. Dichotomous data were reported as percentages
and compared with x2 or Fisher’s exact test. P values are two tailed
with signiﬁcance at ,0.05 (R software environment, version 3.4.0).
Results
Mp-DNA was detected by PCR in 29% (n= 44/152) of patients with
CAP and 8% (n=12/156) of control individuals (P, 0.001). We were
able to perform a complete diagnostic work-up for Mp in 63 patients
with CAP and 21 control individuals (n=12 elective surgery; n=9
siblings), which included the Mp-IgM-ASC ELISpot assay of fresh
peripheral blood mononuclear cells and Mp-IgM ELISA from serum
samples. Chest X-rays were routinely performed in 60 (95%) of 63
included patients with CAP, and 98% (n=59/60) met the World
Health Organization criteria for radiological pneumonia.
In the CAP series, Mp-DNA was detected by PCR in 32 (51%)
patients, 29 (46%) of whom showed positive responses in the
Mp-IgM-ASC ELISpot assay (P= 0.722; Figure 1). In the three Mp
PCR-positive patients with CAP who tested negative for Mp-IgM-
ASCs, another pathogen was found based on the results of
multiplex PCR from pharyngeal swab samples and speciﬁc serology
(Table 1). All patients who were Mp PCR positive and Mp-IgM-
ASC positive were also Mp-IgM seropositive, but Mp-IgM was also
found in 3 (10%) patients with CAP who tested negative by Mp
PCR and Mp-IgM-ASC ELISpot assay.
Pharyngeal swab and blood samples were collected at inclusion
(n=84) and follow-up visits (n=52, 41 patients with CAP and 11
control individuals) and resulted in more than two visits in 42 (81%)
and more than three visits in 27 (52%) children, performed at
,2 weeks (n=43), 2 weeks to 2 months (n=38), and 2–6 months
(n=38). In contrast to Mp-IgM-ASCs, which were found only within
6 weeks after symptom onset, Mp-DNA and/or Mp-IgM persisted
>4 months in 7 (11%) patients with CAP. Only 10 (34%) Mp-IgM-
ASC–positive patients showed a>4-fold increase inMp-IgG, whereas
the remaining (n=19, 66%) had signiﬁcantly increased Mp-IgG
already in ﬁrst serum samples (median, 49 U/ml; range, 20–125 U/ml;
cutoff, 15 U/ml), making a >4-fold increase very unlikely.
Among control subjects, Mp-DNA was detected by PCR in
10 (48%) children. All of these tested negative for Mp-IgM-ASCs
(P, 0.001; Figure 1). Six (29%) control individuals had positive
Mp-IgM, of whom 1 (5%) showed a >4-fold increase in Mp-IgG at
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Figure 1. (A–C) Comparison of diagnostic test results between patients with community-acquired pneumonia (CAP) (n=63; median age, 6.0 yr; interquartile
range [IQR], 4.4–10.2 yr) and control subjects (n=21; median age, 6.1 yr; IQR, 4.9–7.9 yr). CAP samples were collected at disease presentation with a
median of 12 days after onset of symptoms (IQR, 11–16; range, 2–29). PCR-positive patients with CAP testing negative for Mycoplasma pneumoniae
(Mp)-IgM–antibody-secreting cells (ASCs) are indicated in black. Differences in medians are shown with the corresponding P value (Mann-Whitney U test). (A)
Mp-DNA levels in pharyngeal swab samples. (B)Mp-IgM levels. The dashed line represents the cutoff for the test (17 U/ml), with a lower limit of quantification
of 5 U/ml. (C)Mp-IgM-ASC responses. (D–F)Mp-IgM-ASC enzyme-linked immunospot (ELISpot) assay. Assays were performed as described previously (10)
and were specific for the following antigens:Mp (detergent extract enriched for highly specific adhesion protein P1, 2 mg/ml; Virion/Serion), influenza A and B
virus (FluarixTetra quadrivalent influenza virus vaccine, 6 mg/ml; GlaxoSmithKline), and total IgM (affinity-purified antibodies to human immunoglobulin light
chains l and k as positive control, 10 mg/ml; Southern Biotech). The negative control consisted of phosphate-buffered saline (PBS) only in uncoated wells.
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follow-up. Although 4 (19%) control subjects were serologically or
PCR positive for up to 2 months, Mp-IgM-ASC responses were
undetectable during 6-month follow-up.
Discussion
In this longitudinal observational study, the measurement of
Mp-IgM-ASCs by ELISpot assay allowed a differentiation
between infection and carriage. We detected Mp-IgM-ASCs as
early as 2 days after symptom onset, with a peak at presentation
of CAP at median 12 days. Another previous study about Mp-
IgM-ASCs in 12 Mp-seropositive children with CAP
corroborated these ﬁndings (11). The inclusion of asymptomatic
carriers in our study was essential to assess the usefulness of
Mp-IgM-ASC detection as a diagnostic test that can
distinguish between carriage and infection.
In the absence of a “gold standard” for Mp infection
diagnosis, the discriminative potential of the Mp-IgM-ASC
ELISpot assay could not be quantiﬁed by measures of diagnostic
accuracy such as sensitivity and speciﬁcity (12). In fact, if a
unanimously accepted reference standard is lacking, alternative
study designs, as the longitudinal observational study design
chosen in this study, may be more appropriate than test
accuracy studies to determine the beneﬁt of a new diagnostic test
(12). However, it is important to note that our study
population represents a convenience sample from a hypothesis-
generating single-center study with small control group
and longitudinal follow-up in only two-thirds of the children,
Figure 1. (Continued). Representative patterns of ELISpot wells with 10,000 peripheral blood mononuclear cells (PBMCs) per well are shown. Spots were
counted by an ELISpot reader (AID) using predefined settings. The spots identified by the machine were manually inspected for the presence of artifacts.
Antigen-specific spot counts were calculated as the mean of three wells minus the mean number of spots in PBS wells. Data were expressed as ASCs per
106 PBMCs (10). Corresponding chest X-rays of patients with CAP are shown on the right. The pulmonary infiltrate is indicated with a frame. (D) Mp PCR-
positive CAP. (E) Mp PCR-negative CAP. (F) Mp PCR-positive healthy control (carrier). Notably, although the applied protocol has a rather long overall
turnaround time (z24 h), alternative protocols were developed recently that suggest more rapid (z6–8 h) ASC detection (10). Optimizing such protocols in the
future may help translate the Mp-IgM-ASC ELISpot assay into routine clinical care. HC=healthy control.
Table 1. Diagnosis of Patients with CAP Who Are PCR Positive for Mp but Negative by Mp-IgM-ASC ELISpot Assay
Patient 1 Patient 2 Patient 3
Demographic characteristics
Age, yr 4.5 5.9 3.4
Sex M M M
Microbiological characteristics
PCR
Mp-genomic copy numbers/ml* 415 213 177




Time point of serum sample collection after
onset of symptoms, d
1 7 20 12 19 40
Mp-speciﬁc antibodies Negative Negative Negative Negative Negative Negative
IgM, <17 U/ml 5 13 12 ,5 ,5 ,5
IgG, <15 U/ml ,3 3 ,3 ,3 ,3 ,3
IgA, <14 U/ml ,2 ,2 ,2 ,2 ,2 ,2
C. pneumoniae–speciﬁc antibodies Negative Negative Negative — — —
IgM, ,10 U/ml 5 8 9 — — —
IgG, ,10 U/ml ,4 ,4 ,4 — — —
Adenovirus-speciﬁc antibodies Positive Positive Positive — — —
IgM, ,1 Index ,1 ,1 ,1 — — —
IgG, ,13 U/ml 19 23 24 — — —
RSV-speciﬁc antibodies — — — — Positive Positive
IgM, ,1 Index — — — — ,1 ,1
IgG, ,15 U/ml — — — — 27 16
Diagnosis Adenovirus Rhinovirus RSV A
Definition of abbreviations: ASC=antibody-secreting cell; CAP= community-acquired pneumonia; Mp=Mycoplasma pneumoniae; RSV= respiratory
syncytial virus.
Bold indicates the summary and conclusion of all testing in the table.
*All three patients with CAP had significantly lower pharyngeal Mp-DNA levels than Mp-IgM-ASC ELISpot-positive patients with CAP (Figure 1).
†The multiplex PCR FTD Respiratory pathogens 21 (FTD21) assay (Fast-track Diagnostics) was used to test for respiratory pathogens other than Mp in these
three patients. Notably, we are unable to provide information on cocolonization or coinfection in other patients with CAP and control individuals, as we did not
systematically test for other pathogens. However, Mp was recently shown to frequently coexist with other bacterial and viral pathogens in the upper respiratory
tract of both symptomatic and asymptomatic children (1, 2). Therefore, detection of other pathogens would likely not have changed the conclusions of this study.
‡Serum samples were tested with Serion ELISA classic tests (Virion/Serion). No serological assay was available for rhinovirus. It is important to note that
reinfections are often characterized by weak or absent specific IgM antibody responses (3, 8).
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at pragmatically arranged visits instead of standardized weekly
follow-ups. We thus cannot rule out that unintended selection
bias occurred. A larger conﬁrmatory study is needed, now that
the potential for the Mp-IgM-ASC ELISpot assay has been
shown. Improving the early diagnosis of Mp infection in patients
with CAP by the Mp-IgM-ASC ELISpot assay may help future
interventional studies assessing the effect of antimicrobial
treatment in the management of Mp CAP (5, 6). n
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Understanding Hyperlactatemia in Sepsis: Are We
There Yet?
To the Editor:
High plasma lactate is a useful indicator of shock, a canary in the
coal mine, that is associated with increased mortality in sepsis.
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